Lannett Co. plans to transfer the listing of its common stock to the New York Stock Exchange (NYSE) from NYSE MKT.


Lannett, New York Stock Exchange, NYSE, common stock, Arthur Bedrosian, generic pharmaceutical company
































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Lannett to be listed on NYSE

December 2nd, 2013

PHILADELPHIA – Lannett Co. plans to transfer the listing of its common stock to the New York Stock Exchange (NYSE) from NYSE MKT.

The generic pharmaceutical company said Monday that it expects its shares to begin trading on the NYSE as of Dec. 13 under its current ticker symbol, LCI.

"This has been a tremendous year for our company," stated Arthur Bedrosian, president and chief executive officer of Lannett. "We generated record sales and net income, crossed the billion-dollar market cap threshold and raised more than $70 million in a highly successful public offering. Capping these achievements is the listing of our common stock on the Big Board. We have reached an inflection point and are excited about Lannett's future."

Advertisement